2Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran

Background: One of the most difficult side effects of hematopoietic stem cell transplantation is hemorrhagic cystitis (HC) (HSCT). One of the recommended remedies for tackling this issue is oestrogen.

Subjects and Approaches: To assess the effectiveness of oral conjugated oestrogen on HC management in 56 HSCT patients, we conducted a randomised case-control research. Patients were randomised to either the medication group (got oral tablets containing 6.25 mg of conjugated oestrogen once daily during the hematuria phase) or the control group.

Conclusion: The use of oral conjugated oestrogen in the treatment of HC was not shown to be beneficial in our study. Keywords: conjugated oestrogen, hemorrhagic cystitis of late onset and hematopoietic stem cell transplant

Hematopoietic undifferentiated cell transplantation (HSCT) is a critical stage in the administration of hematologic problems. High-portion myeloablative chemotherapy preceding HSCT is required which can lead to different unfavorable effects.1 Quite possibly of the most serious intricacies following HSCT is hemorrhagic cystitis (HC).2,3 Most normal causes of HC incorporate chemotherapeutic specialists (for example cyclophosphamide, isofosfamide, and busulfan), viral contaminations, join versus have illness (GVHD),furthermore, light. HC happens in 10 to 40 percent of

patients who get high-portion chemotherapies.[4] Dying, as a typical indication of HC, is reviewed as gentle, moderate, and extreme. Extreme HC can be dangerous and hemodynamic dependability ought to be monitored.[5,6]Taking into account the hour of event, HC is arranged in two substances. HC that starts inside a couple of days after transplantation is considered as beginning stage, while late-beginning HC happens after [7]days.Beginning stage HC is generally ascribed to cyclophosphamide, and late-beginning HC is by and large due to viral infections.[9]

The administration of HC incorporates hydration, bladder water system, torment control, furthermore, antiviral specialists. Utilization of formalin, prostaglandin E1, factor VIIa, factor XIII, hyperbaric oxygen,The use of recombinant human epidermal growth factor and intravesicular sodium hyaluronate in the treatment of HC is still debatable. 9-12 Additionally, some studies have revealed that conjugated oestrogen may be a useful treatment option for HC in HSCT patients, albeit its exact mode of action is unknown. 13-15 This investigation looked at how oestrogen affects HSCT patients with late-onset HC's ability to control bleeding.

Design and environment,The Hematology-Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences (TUMS), Tehran, Iran, was the site of this case-control randomised clinical trial investigation. The institutional review board gave its approval to the study protocol as well as the data collecting and analysis procedures. Before any study-related interventions, all recruited patients gave written, informed permission to the study protocol in accordance with the Helsinki declaration.

The study included adult patients with late-onset HC receiving allogenic HSCT. Inclusion criteria included patients receiving a conditioning regimen, myeloablative chemotherapy (busulfan and cyclophosphamide), or nonmyeloablative chemotherapy (busulfan and fludarabine). Patients with active hepatic disease (defined as bilirubin more than 3.0 mg per dL, AST or ALT more than 2 times above the upper limit of normal), nephrolithiasis, history or high risk of venous thromboembolism, and triglycerides more than 300 mg per dL were excluded, while patients with bacterial urinary tract infections, platelet count less than 20,000 per L, prothrombin time longer

Based on balanced block randomization, patients were assigned at random to the medication or control group. All patients got the conventional HC therapies, such as diuretics or intravenous or oral hydration, bladder irrigation, or urine catheterization. Patients in the medication group got 6.25 mg of conjugated oestrogen orally once daily until the hematuria resolved. Following HSCT, patients received regular monitoring for 100 days.

Data on the patients' demographics, physical examination, and test results were collected. Laboratory data including baseline and subsequent weekly urine analyses (UA), complete blood counts (CBC), and liver function tests (LFTs). The severity of the HC haemorrhage was categorised using the Bearman et al. grading system. Conjugated estrogen-related side effects were evaluated. The two key outcome measures were time to downstage and time to complete reaction (CR).

Comparing continuous and categorical data between two groups was done using the Mann-Whitney U test and the Chi-square test, respectively. The Kaplan-Meier estimator was used to assess the likelihood of a complete response and the down stage, and the log-rank test was used to compare the probabilities between groups. The groups were compared using a proportional Cox regression model that was adjusted for various baseline factors (such as HC grades). SPSS version 17 (SPSS Inc, Chicago, IL, USA) was used for the statistical analysis. The threshold for significance was set at a P-value of less than 0.05.

Hemorrhagic cystitis is a significant issue for patients going through HSCT which could prompt death.16 Albeit various variables are associated with the pathogenesis of late-beginning HC, the etiology is not plainly perceived yet.17 Conceivable gamble factors are viral diseases (like adenoviruses,18-20 polyomavirus,21 and cytomegaloviruses22), join versus have disease23 and thrombocytopenia.17 Despite the fact that avoidance is the critical procedure for HC the board in chemotherapy systems, there are a few clinical mediations too. Patients ought to be treated with hydration and constrained diuresis. Torment is overseen by analgesics, for example,

opiates and spasmolytics. In grade 3 HC, bladder water system is important to forestall bladder tamponade. HC with obstructive side effects is an crisis condition and ought to be treated with an intrusive methodology including blood cluster departure.Intravesicular modalities like Alum implantation,formalin, phenol in different focuses may likewise be used.11,24-28 Hydronephrosis and urethral injury were accounted for as the confusions of last methods.29 A few investigations recommended that the utilization of rh GM-CSF, sodium hyaluronate, and progtoglandin E1 could find actual success choices, even however wellbeing and viability of not a single one of them have been established.9-12 One more proposed treatment elective for HC is formed estrogen, in light of a few reports. Estrogen might meaningfully affect the microvascular adjustment in the bladder wall.9, 13-15 In this review, formed estrogen showed no valuable impact in the treatment of HC related with HSCT. Be that as it may, a few past examinations have

announced further developing impacts of estrogen on HC.1990, Liu et al. revealed five patients effectively been treated with intraveneous and oral estrogen with no unfavorable responses despite the fact that apoplexy was detailed as the principal risk.13 Mill operator et al.recorded a total reduction pace of 86% (6 of 7 patients) with oral estrogen.14 In another review distributed by Ordemann et al. 7 out of 10 grown-up patients (70%) exhibited positive outcomes.15 In a report of 10 kids and teenagers treated with estrogen for HC following HSCT, Heath et al. shown 80% improvement of hematuria, 60% goal of perceptible hematuria, with practically no repeats. Despite the fact that estrogen was very much endured by most patients, one patient created hepatotoxicity that prompted drug discontinuation.9 Various consequences of our preliminary may be expected to lacking portion of formed estrogen directed to the patients. Additionally, the majority of the past investigations have started the treatment with injectable types of estrogen that could have been more viable in the fast administration of HC;in any case, just the oral type of formed estrogen was utilized in our review.

Treatment of HC related to HSCT with oral conjugated oestrogen did not work. To assess the safety and effectiveness of this medication in the treatment of HC after HSCT, large randomised placebocontrolled clinical studies should be conducted. Different oestrogen dosages and administration methods should also be examined.

The staff members of Shariati Hospital's BMT Wards 1, 2, and 4 are appreciated for their contributions to this study. The study was carried out at the Tehran University of Medical Sciences' Hematology-Oncology and SCT Research Center in Tehran, Iran.

1. Copelan EA. Hematopoietic stem-cell transplantation.N Engl J Med. 2006; 354(17):1813-26.

2. Ilhan O, Koc H, Akan H, et al. Hemorrhagic cystitis as a complication of bone marrow transplantation. J Chemother. 1997; 9(1):56-61.

3. Efros MD, Ahmed T, Coombe N, et al. Urologic complications of high-dose chemotherapy and bone marrow transplantation. Urology. 1994; 43(3):355-60.

4. Watson NA, Notley RG. Urological Complications of Cyclophosphamide. Br J Urol. 1973; 45(6):606-09.

5. Gorczynska E, Turkiewicz D, Rybka K, et al. Incidence, Clinical Outcome, and Management of Virus-Induced Hemorrhagic Cystitis in Children and Adolescents after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2005; 11(10):797-804.

6. Cesaro S, Brugiolo A, Faraci M, et al. Incidence and treatment of hemorrhagic cystitis in children given, hematopoietic stem cell transplantation: a survey from the Italian association of pediatric hematology oncology–bone marrow transplantation group. Bone Marrow Transplant. 2003; 32(9):925-31.

7. Leung AY, Yuen KY, Kwong YL. Polyoma BK virus and haemorrhagic cystitis in haematopoietic stem cell transplantation: a changing paradigm. Bone Marrow Transplant. 2005; 36(11):929-37.

8. Howard DS, Phillips GL, Reece DE, et al. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 1999; 29(6):1494-1501.

9. Heath JA, Mishra S, Mitchell S, et al. Estrogen as treatment of hemorrhagic cystitis in children and adolescents undergoing bone marrow transplantation.Bone Marrow Transplant. 2006; 37(5):523-6.

10. Cheuk DK, Lee TL, Chiang AK, et al. Risk factors and treatment of hemorrhagic cystitis in children who underwent hematopoietic stem cell transplantation.Transpl Int. 2007; 20(1):73-81.

11. Mukamel E, Lupu A, DeKernion JB. Alum irrigation for severe bladder hemorrhage. J Urol. 1986; 135(4):784-5.

12. Trigg ME, O'Reilly J, Rumelhart S, et al. Prostaglandin E1 bladder instillations to control severe hemorrhagic cystitis. J Urol. 1990; 143(1):92-4.

13. Liu YK, Harty JI, Steinbock GS, et al. Treatment of radiation or cyclophosphamide induced hemorrhagic cystitis using conjugated estrogen. J Urol. 1990;144(1):41-3.

14. Miller J, Burfield GD, Moretti KL. Oral conjugated estrogen therapy for treatment of hemorrhagic cystitis. J Urol. 1994; 151(5):1348-50.

15. Ordemann R, Naumann R, Geissler G, et al.Encouraging results in the treatment of haemorrhagic cystitis with estrogen–report of 10 cases and review of the literature. Bone Marrow Transplant. 2000; 25(9):981-5.

16. Brugieres L, Hartmann O, Travagli J, et al.Hemorrhagic cystitis following high-dose chemotherapy and bone marrow transplantation in children with malignancies: incidence, clinical course and outcome. J Clin Oncol. 1989; 7:194-9.

17. Lunde LE, Dasaraju S, Cao Q, et al. Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. Bone Marrow Transplant. 2015; 50(11):1432-7.

18. Shields AF, Hackman RC, Fife KH, et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med. 1985; 312(9):529-33.

19. Ambinder RF, Burns W, Forman M, et al. Hemorrhagic cystitis associated with adenovirus infection in bone marrow transplantation. Arch Intern Med. 1986; 146(7):1400-1.

20. Miyamura K, Takeyama K, Kojima S, et al.Hemorrhagic cystitis associated with urinary excretion of adenovirus type 11 following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1989;4(5):533-5.

21. Arthur RR, Shah KV, Baust SJ, et al. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplants. N Engl J Med. 1986; 315(4):230-4.

22. Goldman RL, Warner NE. Hemorrhagic cystitis and cytomegalic inclusions in the bladder associated with cyclophosphamide therapy. Cancer. 1970; 25(1):7-11.

23. Trotman J, Nivison-Smith I, Dodds A. Haemorrhagic cystitis: incidence and risk factors in a transplant population using hyperhydration. Bone Marrow Transplant. 1999; 23(8):797-801.

24. Donahue LA, Frank IN. Intravesical formalin for hemorrhagic cystitis: analysis of therapy. J Urol. 1989;141(4):809-12.

25. Susan LP, Marsh RJ. Phenolization of bladder in treatment of massive intractable hematuria. Urology. 1975; 5(1):119-21.

26. Vela-Ojeda J, Tripp-Villanueva F, Sanchez-Cortes E, et al. Intravesical rhGM-CSF for the treatment of late onset hemorrhagic cystitis after bone marrow transplant. Bone Marrow Transplant. 1999; 24(12):.1307-10.

27. Miodosky M, Abdul-Hai A, Tsirigotis P, et al.Treatment of post-hematopoietic stem cell transplantation hemorrhagic cystitis with intravesicular sodium hyaluronate. Bone marrow transplantation 2006;38(7):507-11.

28. Levine LA, Jarrard DF. Treatment of cyclophosphamide-induced hemorrhagic cystitis with intravesical carboprost tromethamine. J Urol. 1993; 149(4):719-23.

29. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996; 348(9033):977-80.

Niayesh Mohebbi . The Role of Conjugated Estrogen in Late-Onset Hemorrhagic Cystitis Associated with Hematopoietic Stem Cell Transplantation. World Journal Of Hematology And Oncology 2022.